CIK 0000842023 · Large accelerated filer
BIO-TECHNE Corp
Sign in to watch- Ticker
- TECH
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jun 30
- Incorporated
- MN
- Entity type
- operating
- EIN
- 411427402
- Phone
- 612-379-8854
- Business address
- 614 MCKINLEY PLACE NE, MINNEAPOLIS, MN
- Former names
- TECHNE CORP /MN/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-08-18 | Bazan J. Fernando Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +14,476 | 14,476 | ||
| 2016-08-18 | Bazan J. Fernando Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +10,857 | 10,857 | ||
| 2016-08-18 | Bazan J. Fernando Chief Technical Officer | Grant or award · Restricted Stock Units | +1,759 | 1,759 | ||
| 2016-08-18 | Gavin Robert M. Senior V.P. Protein Platforms | Grant or award · Stock Option (Right to Buy) | +17,371 | 17,371 | ||
| 2016-08-18 | Gavin Robert M. Senior V.P. Protein Platforms | Grant or award · Stock Option (Right to Buy) | +13,028 | 13,028 | ||
| 2016-08-18 | Gavin Robert M. Senior V.P. Protein Platforms | Grant or award · Restricted Stock Units | +2,111 | 2,111 | ||
| 2016-08-18 | Gould Kevin S SVP Clinical Controls | Grant or award · Stock Options (Right to Buy) | +17,371 | 17,371 | ||
| 2016-08-18 | Gould Kevin S SVP Clinical Controls | Grant or award · Stock Options (Right to Buy) | +13,028 | 13,028 | ||
| 2016-08-18 | Gould Kevin S SVP Clinical Controls | Grant or award · Restricted Stock Units | +2,111 | 2,111 | ||
| 2016-08-18 | Furlow Brenda S. SVP - General Counsel | Grant or award · Stock Option (Right to Buy) | +14,476 | 14,476 | ||
| 2016-08-18 | Furlow Brenda S. SVP - General Counsel | Grant or award · Stock Option (Right to Buy) | +10,857 | 10,857 | ||
| 2016-08-18 | Furlow Brenda S. SVP - General Counsel | Grant or award · Restricted Stock Units | +1,759 | 1,759 | ||
| 2016-08-18 | Eansor Norman David SVP - Biotech | Grant or award · Stock Option (Right to Buy) | +18,819 | 18,819 | ||
| 2016-08-18 | Eansor Norman David SVP - Biotech | Grant or award · Stock Option (Right to Buy) | +14,114 | 14,114 | ||
| 2016-08-18 | Eansor Norman David SVP - Biotech | Grant or award · Restricted Stock Units | +2,287 | 2,287 | ||
| 2016-08-18 | Hippel James Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +40,533 | 40,533 | ||
| 2016-08-18 | Hippel James Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +30,400 | 30,400 | ||
| 2016-08-18 | Hippel James Chief Financial Officer | Grant or award · Restricted Stock Unit | +4,925 | 4,925 | ||
| 2016-08-18 | Kummeth Charles R. Chief Executive Officer | Grant or award | +16,653 | 61,030 | ||
| 2016-08-18 | Kummeth Charles R. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +102,779 | 102,779 |
Page 62 of 64 · 1,274 trades